Redwood Investments LLC grew its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 70.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 225,476 shares of the company’s stock after acquiring an additional 93,114 shares during the period. Omnicell comprises about 1.3% of Redwood Investments LLC’s investment portfolio, making the stock its 23rd biggest position. Redwood Investments LLC’s holdings in Omnicell were worth $18,227,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in OMCL. State of Alaska Department of Revenue lifted its position in shares of Omnicell by 3.4% in the fourth quarter. State of Alaska Department of Revenue now owns 13,248 shares of the company’s stock valued at $811,000 after acquiring an additional 437 shares in the last quarter. First Hawaiian Bank lifted its position in shares of Omnicell by 121.2% in the fourth quarter. First Hawaiian Bank now owns 1,369 shares of the company’s stock worth $84,000 after buying an additional 750 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Omnicell in the fourth quarter worth about $372,000. Virtu Financial LLC purchased a new stake in shares of Omnicell in the fourth quarter worth about $396,000. Finally, Meeder Asset Management Inc. purchased a new stake in shares of Omnicell in the fourth quarter worth about $35,000. Institutional investors and hedge funds own 96.35% of the company’s stock.
NASDAQ OMCL traded down $0.73 during trading hours on Friday, hitting $80.45. 20,529 shares of the company were exchanged, compared to its average volume of 361,257. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.96 and a quick ratio of 1.47. Omnicell, Inc. has a 52 week low of $45.15 and a 52 week high of $86.87. The stock has a market capitalization of $3.38 billion, a P/E ratio of 52.58, a PEG ratio of 2.66 and a beta of 1.20.
In other Omnicell news, CEO Randall A. Lipps sold 24,282 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $79.01, for a total transaction of $1,918,520.82. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Peter J. Kuipers sold 1,044 shares of the business’s stock in a transaction that occurred on Saturday, March 9th. The stock was sold at an average price of $44.34, for a total value of $46,290.96. Following the sale, the chief financial officer now directly owns 56,873 shares in the company, valued at $2,521,748.82. The disclosure for this sale can be found here. Insiders have sold 199,464 shares of company stock worth $15,226,091 over the last three months. 2.77% of the stock is currently owned by insiders.
A number of equities research analysts recently commented on the company. BidaskClub upgraded Omnicell from a “sell” rating to a “hold” rating in a research report on Saturday, May 4th. Zacks Investment Research downgraded Omnicell from a “hold” rating to a “sell” rating in a research report on Monday, March 25th. Five equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $79.89.
WARNING: “Omnicell, Inc. (OMCL) Shares Bought by Redwood Investments LLC” was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/05/17/omnicell-inc-omcl-shares-bought-by-redwood-investments-llc.html.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Recommended Story: What economic reports are most valuable to investors?
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.